Bristol-Myers Squibb Company (BMY)
NYSE · Princeton, New Jersey, USA · Founded 1887 · CEO Christopher Boerner
Valuation summary
$101.92 fair value versus $58.34 in the market, a difference of +74.7%. Rated Strong Buy.
| Fair value per share | $101.92 |
| Current share price | $58.34 |
| Upside / downside | +74.7% |
| Bear case | $69.53 |
| Bull case | $146.05 |
| Discount rate (WACC) | 9.4% |
| Terminal growth | 2.00% |
| Market capitalisation | $119B |
| EV / Sales | 3.0x |
About Bristol-Myers Squibb Company
Traces to Bristol-Myers, founded 1887, merged with Squibb in 1989. Christopher Boerner became CEO in late 2023. Bristol Myers Squibb sells Eliquis, the leading blood thinner, and Opdivo, a foundational cancer immunotherapy. Both face loss of exclusivity within a few years, and the company has made a series of large acquisitions — Karuna, RayzeBio, Mirati — to rebuild the pipeline. Cobenfy, a novel schizophrenia treatment from Karuna, is the most important new launch.
Investment case
- Cobenfy is the first genuinely new mechanism in schizophrenia in decades and addresses a large underserved population.
- Trades at one of the lowest multiples in large-cap pharma with a substantial dividend.
- Strong current cash generation funds both the dividend and continued business development.
Key risks
- Eliquis and Opdivo together represent a very large share of revenue and both face exclusivity loss.
- Recent acquisitions have been expensive and have not yet demonstrated returns.
- US drug pricing reform disproportionately affects the highest-revenue products.
Recent developments
- 2026-10-29 · Q3 revenue up 6.9% to $13.07bn beats; 2026 revenue guide lifted to about $50bn while the EPS guide is cut on an in-process R&D charge source
- 2026-10-05 · Leerink downgraded BMS to Market Perform and cut its target to $59 from $73, doubting milvexian, admilparant and Cobenfy in Alzheimer's psychosis; shares fell about 4%. source
- 2026-09-30 · FDA approved an expanded Camzyos indication for symptomatic obstructive hypertrophic cardiomyopathy, including paediatric patients. source
- 2026-09-25 · Phase 3 EXCALIBER-RRMM: Zenbexus (iberdomide) with daratumumab met its MRD-negative complete response primary endpoint in relapsed multiple myeloma. source
Revenue by segment
| Oncology | 40% |
| Cardiovascular | 27% |
| Immunology | 20% |
| Neuroscience & Other | 13% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $51.9B | $17.7B |
| Year 2 | $54.1B | $17.8B |
| Year 3 | $56.3B | $17.8B |
| Year 4 | $58.6B | $17.8B |
| Year 5 | $61.1B | $17.8B |
What the street says
A classic value-versus-patent-cliff debate, now focused on a cluster of pipeline readouts. In October 2026 Leerink downgraded to Market Perform with a $59 target, doubting milvexian against Eliquis, admilparant and Cobenfy in Alzheimer's disease psychosis, while Piper Sandler had raised its target to $82 in September on the same milestones.
Comparable companies: DHR · GSK · PFE · AMGN · NVO · GILD · ZTS · TAK
Open the interactive model, price chart and sensitivity grid →